Recombinant human plasma gelsolin

Summary

Recombinant human plasma gelsolin is an 80 kDa actin-severing protein under clinical investigation for conditions associated with plasma gelsolin depletion and actin release, including acute respiratory distress syndrome (ARDS), COVID-19 complications, and other critical illness states. Plasma gelsolin is normally abundant in blood and acts as a physiological buffer against extracellular actin toxicity; levels fall dramatically during severe injury or infection.

Mechanism of Action

Recombinant human plasma gelsolin (rhu-pGSN) severs and caps actin filaments released into the extracellular space during cell injury or death, reducing actin-mediated inflammatory signaling, scavenging lysophospholipids and other bioactive lipids, and restoring depleted plasma gelsolin levels to attenuate systemic inflammatory responses.

Routes of Administration

Goals & Uses

• Scavenging extracellular actin in critical illnessPathophysiology CorrectionModerate
• Acute kidney injury prevention in critical illnessNephrologyLow
• Attenuation of ARDS / acute lung injuryCritical Care / PulmonologyModerate
• Reduction of systemic inflammation in sepsisAnti Inflammatory / Critical CareLow
• COVID-19 severe disease managementInfectious Disease / Critical CareLow

Contraindications

• Severe uncontrolled coagulopathyHematologyModerate
• Known hypersensitivity to recombinant human proteins or CHO-derived productsAllergy / ImmunologyHigh

Adverse Effects

• Headache / myalgiaGeneralUncommon
• Anti-drug antibody formationImmunologicalUnknown
• Infusion-related reactionsHypersensitivityUncommon
• Transient hypotensionCardiovascularUncommon

Drug Interactions

• Other recombinant protein biologicsLow
• Anticoagulants (e.g., heparin, warfarin)Low

Population Constraints

• Pediatric patientsAgeRelative
• Pregnant or lactating womenReproductiveRelative
• Patients with pre-existing autoimmune conditionsImmunologicRelative
• Renal or hepatic impairmentOrgan DysfunctionRelative

Regulatory Status

• European UnionInvestigationalNo EMA marketing authorization. Investigational use under clinical trial frameworks.
• United StatesInvestigationalIND-stage; Phase I/II clinical trials conducted. No NDA or BLA filed as of 2024. Potential orphan drug designation for specific indications explored.
• United KingdomInvestigationalNo MHRA approval. Clinical trial access only.

No FDA, EMA, or MHRA marketing approval as of 2024. Designated as an orphan drug candidate for certain indications in exploratory trials. Developed primarily by BioAegis Therapeutics. Multiple Phase I/II trials conducted.

Evidence & Sources

No sources recorded yet.